Legend Biotech (LEGN)

• Market cap: $6.33B
• 1 day: -1.24%
• 5 days: -4.00%
• 1 month: -17.39%
• 3 months: 21.21%
• 6 months: -2.06%
• Year to date: -1.27%
• 1 year: -39.48%
• 5 years: 0.85%
• 10 years: -7.32%
• Sector: Healthcare
• Industry: Biotechnology

About: Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

Employees: 2,700

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

170% more call options, than puts

Call options by funds: $27.4M | Put options by funds: $10.2M

24% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 29

22.25% more ownership

Funds ownership: 23.57% [Q1] → 45.82% (+22.25%) [Q2]

3% more capital invested

Capital invested by funds: $2.91B [Q1] → $2.99B (+$81M) [Q2]

1% more funds holding

Funds holding: 204 [Q1] → 206 (+2) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 7 [Q1] → 7 (+0) [Q2]

17% less repeat investments, than reductions

Existing positions increased: 70 | Existing positions reduced: 84

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $54 57% upside
• Avg. target: $72 110% upside
• High target: $83 142% upside

6 analyst ratings

• positive: 6 100%
• neutral: 0 0%
• negative: 0 0%

Cantor Fitzgerald Eric Schmidt	92% upside $66	Overweight Assumed	27 Aug 2025
JP Morgan Jessica Fye	127% upside $78	Overweight Maintained	25 Aug 2025
RBC Capital Leonid Timashev	125% upside $77	Outperform Maintained	12 Aug 2025
Morgan Stanley Matthew Harrison	142% upside $83	Overweight Maintained	12 Aug 2025
HC Wainwright & Co. Mitchell Kapoor	119% upside $75	Buy Reiterated	17 Jul 2025